KNRS

Kinarus Therapeutics Holding SWX:KNRS Stock Report

Last Price

CHF0.029

Market Cap

CHF30.6m

7D

-1.4%

1Y

n/a

Updated

16 Aug, 2022

Data

Company Financials
KNRS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

KNRS Stock Overview

Perfect Holding SA, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases.

Kinarus Therapeutics Holding AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kinarus Therapeutics Holding
Historical stock prices
Current Share PriceCHF0.029
52 Week HighCHF0.051
52 Week LowCHF0.024
Beta0
1 Month Change2.14%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-28.50%

Recent News & Updates

Shareholder Returns

KNRSCH AirlinesCH Market
7D-1.4%5.2%0.08%
1Yn/a-22.5%-12.9%

Return vs Industry: Insufficient data to determine how KNRS performed against the Swiss Airlines industry.

Return vs Market: Insufficient data to determine how KNRS performed against the Swiss Market.

Price Volatility

Is KNRS's price volatile compared to industry and market?
KNRS volatility
KNRS Average Weekly Movement17.2%
Airlines Industry Average Movement6.3%
Market Average Movement4.5%
10% most volatile stocks in CH Market7.8%
10% least volatile stocks in CH Market2.4%

Stable Share Price: KNRS is more volatile than 90% of Swiss stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: Insufficient data to determine KNRS's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/an/ahttps://www.kinarus.com

Perfect Holding SA, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 MAPK inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company is based in Lausanne, Switzerland.

Kinarus Therapeutics Holding AG Fundamentals Summary

How do Kinarus Therapeutics Holding's earnings and revenue compare to its market cap?
KNRS fundamental statistics
Market CapCHF30.59m
Earnings (TTM)CHF0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KNRS income statement (TTM)
RevenueCHF0
Cost of RevenueCHF0
Gross ProfitCHF0
Other ExpensesCHF0
EarningsCHF0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did KNRS perform over the long term?

See historical performance and comparison